Ulcerative Colitis

Higher cumulative exposure to systemic antibiotic therapy may be associated with higher risk for the development of inflammatory bowel disease, according to research published in Lancet Gastroenterology & Hepatology.

Patients with inflammatory bowel disease discontinued methotrexate therapy at twice the rate seen in those who used optimized thiopurine therapy, according to study results.

Etrolizumab, an investigational drug developed by Genentech, failed to meet the primary maintenance endpoints in several phase 3 trials and had mixed results in other induction studies, according to a company press release.

Current or past smoking was not associated with increased risk for the development of pouchitis in patients with ulcerative colitis, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.

Colorectal cancer screening rates in recent years have significantly decreased in at-risk groups such patients aged 50 to 52 years and patients under 50 years with Crohn’s disease and ulcerative colitis, according to data collected by the Blue Cross Blue Shield Association and reported in The Health of America report, Rise in Chronic Conditions is Putting More Americans at risk for Colorectal Cancer.

Investigators found vancomycin preconditioning followed by SER-287 was significantly more effective compared with placebo for induction of remission in patients with active mild-to-moderate ulcerative colitis.

Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease was safe and well tolerated and resulted in a high rate of C. difficile decolonization, according to a study published in Gastroenterology.

Individuals with atopic diseases such as asthma and atopic dermatitis appeared to be at higher risk for developing inflammatory bowel disease, according to study results.

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

After dysplasia resection in patients with inflammatory bowel disease, risk for colorectal cancer was low, according to results published in Gastrointestinal Endoscopy.